Spravato is a nasal spray prescribed for treatment-resistant depression. Unlike oral antidepressants, which can take several weeks to months to work, the effects of Spravato are typically felt within days, unlocking a pathway to healing for patients who have not responded to oral antidepressants and/or other augmentative therapies alone. Spravato is the first new drug approved for depression by the Federal Drug Administration (FDA) in decades. Spravato is specially designed for those suffering from Treatment Resistant Depression (TRD). Spravato (esketamine) is indicated in combination with an oral antidepressant for adults suffering from treatment-resistant depression. If you have not responded to 2 or more antidepressants or other alternative treatments (such as psychotherapy, TMS, ECT, etc.), Spravato could be right for you!
